The Effectiveness Of AHSG Antibody In Preoperative Diagnosis And Prognosis Evaluation Of Breast Cancer

Objective and MeaningBreast cancer has come to be the most common malignancy in women, and turns to be the main life-threatening cancer for female. Early diagnosis and evaluation of breast cancer could not only optimize disease therapy, but also ameliorate the patient outcome. To date, no blood-based biomarker of breast cancer could satisfy researches and clinical workers, which should be worked out as early as possible. Therefore, for the assistance of preoperative diagnosis and prognosis evaluation of breast cancer, we, according to the published literatures, chose to investigate the sera concentration of human Alpha-2-Heremans Schmid (HS)-glycoprotein (AHSG) antibody in preoperative breast cancers so as to figure out the feasibility and effectiveness of this antibody in early diagnosis of breast cancer, including the correlation with clinicopathology characteristics. Intend to find a new direction in the journey of seeking the specific tumor marker for cancer.MethodsBlood Sera samples were randomly obtained from breast tumor patients coming to the Department of Thyroid and Breast Surgery, Subei People’s Hospital of Jiangsu Province, China, from Jun 2013 to Sept 2014, including healthy control volunteers, who came for a regular medical check-up and the results of all check-ups, including breast mammography and Doppler Ultrasound, showed nothing that could be considered evidence of malignancy. None of the patients had other malignancies. All the peripheral blood was collected after an overnight fast. And according to the patients characteristics and clinicopathologic descriptions after breast surgery, we at last recruited 89 cases of invasive breast cancer ’of no special type for Breast Cancer group,31 women with breast benign tumors (including 28 cases of breast fibroadenoma and adenosis of breast accompany fibroadenoma neoplasia 3 cases) for breast Benign Tumor group, and 30 age-matched apparently healthy women for the Healthy group. For AHSG antibody, CA153 and CEA assay in the collected sera, a quantitative sandwich enzyme immunoassay technique was used. EXCEL and SPSS20.0 softwares were used for statistical analysis.Results1. AHSG antibody sera level in Breast Cancer group was raised and statistically significant compared with Healthy group and the Benign one (P=0.00<0.01);2. ROC curve could apparently assess diagnosis accuracy, and AHSG antibody, with a AUC of 0.97, should a better diagnosis value than CA153 and CEA. According to the figured out cut-point value (377.97μg/ml) of AHSG antibody, a relatively best accuracy obtained, with a sensitivity of 0.97, specialty 0.94 and Youden index 0.90 respectively. Compared with the pathologically diagnosis report, the diagnose effectiveness of AHSG antibody, CA153 and combination of CA153 and CEA for parallel test (CA153+CEA), but not CEA statistically showed statistical difference, with P=1>0.05、P=0.18>0.05、P=0.47>0.05 and P=0.02<0.05, respectively. The diagnostic accuracy of AHSG antibody statistically surpassed CA153 and CA153+CEA (χ2=46.76、P=0.00<0.05,χ2=37.37、P=0.00<0.05 respectively);3. Comparing AHSG antibody with clinicopathology characteristics of breast cancers: Both AHSG antibody and CA153 level of N2-3 group were higher than the NOs, with P=0.03 <0.05 and P=0.01<0.05 respectively. CA153, but not AHSG antibody of N1 breast cancers, was higher than the NOs (P=0.00<0.05). AHSG antibody and CA153 level in pathology stagingⅢ group were higher than group Ⅰ and Ⅱ, with P value all less than 0.05. CA153 of T2 breast cancers was higher than the Tls (P=0.03<0.05). But no correlation was figured out between AHSG antibody and the other clinicopathology characteristics, including tumor size, histology grade, age of onset, and menstruation state of the breast cancer patients.4. According to the NPI score, for the prognostic evaluation of AHSG antibody in breast cancer, AHSG antibody level of high risk group was higher than the lows and the mids, but with little statistic difference(P>0.05)。In the Spearman correlation analysis, AHSG antibody and CA153 level all had positive correlation with NPI score, with rs=0.23、P=0.03<0.05, rs=0.29、P =0.01<0.05 respectively.Conclusions1. Serum AHSG antibody worked better in the preoperative breast cancer diagnose than CA153, CA153+CEA and CEA, which implied AHSG antibody may serve well as a preoperative diagnosis biomarker for breast cancer screening. Additional studies are required to confirm this.2. The serum AHSG antibody of preoperative breast cancer patients had potential in predicting the breast cancer stages and nodal status, and the role in the evaluation of overall survival. The correlation between serum antibody and tumor deserves attention.